These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 28156048)

  • 1. Targeted O-glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advanced-stage bladder tumours.
    Cotton S; Azevedo R; Gaiteiro C; Ferreira D; Lima L; Peixoto A; Fernandes E; Neves M; Neves D; Amaro T; Cruz R; Tavares A; Rangel M; Silva AMN; Santos LL; Ferreira JA
    Mol Oncol; 2017 Aug; 11(8):895-912. PubMed ID: 28156048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer.
    Peixoto A; Ferreira D; Azevedo R; Freitas R; Fernandes E; Relvas-Santos M; Gaiteiro C; Soares J; Cotton S; Teixeira B; Paulo P; Lima L; Palmeira C; Martins G; Oliveira MJ; Silva AMN; Santos LL; Ferreira JA
    J Exp Clin Cancer Res; 2021 Jun; 40(1):191. PubMed ID: 34108014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia enhances the malignant nature of bladder cancer cells and concomitantly antagonizes protein O-glycosylation extension.
    Peixoto A; Fernandes E; Gaiteiro C; Lima L; Azevedo R; Soares J; Cotton S; Parreira B; Neves M; Amaro T; Tavares A; Teixeira F; Palmeira C; Rangel M; Silva AM; Reis CA; Santos LL; Oliveira MJ; Ferreira JA
    Oncotarget; 2016 Sep; 7(39):63138-63157. PubMed ID: 27542232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics.
    Costa C; Pereira S; Lima L; Peixoto A; Fernandes E; Neves D; Neves M; Gaiteiro C; Tavares A; Gil da Costa RM; Cruz R; Amaro T; Oliveira PA; Ferreira JA; Santos LL
    PLoS One; 2015; 10(11):e0141253. PubMed ID: 26569621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of high-risk of recurrence/progression bladder tumours expressing sialyl-Tn and sialyl-6-T to BCG immunotherapy.
    Lima L; Severino PF; Silva M; Miranda A; Tavares A; Pereira S; Fernandes E; Cruz R; Amaro T; Reis CA; Dall'Olio F; Amado F; Videira PA; Santos L; Ferreira JA
    Br J Cancer; 2013 Oct; 109(8):2106-14. PubMed ID: 24064971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P53 and cancer-associated sialylated glycans are surrogate markers of cancerization of the bladder associated with Schistosoma haematobium infection.
    Santos J; Fernandes E; Ferreira JA; Lima L; Tavares A; Peixoto A; Parreira B; Correia da Costa JM; Brindley PJ; Lopes C; Santos LL
    PLoS Negl Trop Dis; 2014 Dec; 8(12):e3329. PubMed ID: 25502795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sialyl-Tn identifies muscle-invasive bladder cancer basal and luminal subtypes facing decreased survival, being expressed by circulating tumor cells and metastases.
    Lima L; Neves M; Oliveira MI; Dieguez L; Freitas R; Azevedo R; Gaiteiro C; Soares J; Ferreira D; Peixoto A; Fernandes E; Montezuma D; Tavares A; Ribeiro R; Castro A; Oliveira M; Fraga A; Reis CA; Santos LL; Ferreira JA
    Urol Oncol; 2017 Dec; 35(12):675.e1-675.e8. PubMed ID: 28911924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion.
    Gaiteiro C; Soares J; Relvas-Santos M; Peixoto A; Ferreira D; Paulo P; Brandão A; Fernandes E; Azevedo R; Palmeira C; Freitas R; Miranda A; Osório H; Prieto J; Lima L; Silva AMN; Santos LL; Ferreira JA
    Theranostics; 2022; 12(7):3150-3177. PubMed ID: 35547758
    [No Abstract]   [Full Text] [Related]  

  • 9. Different levels of sialyl-Tn antigen expressed on MUC16 in patients with endometriosis and ovarian cancer.
    Akita K; Yoshida S; Ikehara Y; Shirakawa S; Toda M; Inoue M; Kitawaki J; Nakanishi H; Narimatsu H; Nakada H
    Int J Gynecol Cancer; 2012 May; 22(4):531-8. PubMed ID: 22367369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycan affinity magnetic nanoplatforms for urinary glycobiomarkers discovery in bladder cancer.
    Azevedo R; Soares J; Gaiteiro C; Peixoto A; Lima L; Ferreira D; Relvas-Santos M; Fernandes E; Tavares A; Cotton S; Daniel-da-Silva AL; Santos LL; Vitorino R; Amado F; Ferreira JA
    Talanta; 2018 Jul; 184():347-355. PubMed ID: 29674052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico approaches for unveiling novel glycobiomarkers in cancer.
    Azevedo R; Silva AMN; Reis CA; Santos LL; Ferreira JA
    J Proteomics; 2018 Jan; 171():95-106. PubMed ID: 28782717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Target Score-A Proteomics Data Selection Tool Applied to Esophageal Cancer Identifies GLUT1-Sialyl Tn Glycoforms as Biomarkers of Cancer Aggressiveness.
    Cotton S; Ferreira D; Soares J; Peixoto A; Relvas-Santos M; Azevedo R; Piairo P; Diéguez L; Palmeira C; Lima L; Silva AMN; Lara Santos L; Ferreira JA
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted O-glycoproteomics for the development of diagnostic markers for advanced colorectal cancer.
    Takakura D; Ohashi S; Kobayashi N; Tokuhisa M; Ichikawa Y; Kawasaki N
    Front Oncol; 2023; 13():1104936. PubMed ID: 36845686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2-6 sialic acids.
    Loureiro LR; Sousa DP; Ferreira D; Chai W; Lima L; Pereira C; Lopes CB; Correia VG; Silva LM; Li C; Santos LL; Ferreira JA; Barbas A; Palma AS; Novo C; Videira PA
    Sci Rep; 2018 Aug; 8(1):12196. PubMed ID: 30111774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lectin Affinity Chromatography for the Discovery of Novel Cancer Glycobiomarkers: A Case Study with PSA Glycoforms and Prostate Cancer.
    Llop E; Peracaula R
    Methods Mol Biol; 2022; 2370():301-313. PubMed ID: 34611876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein glycosylation in gastric and colorectal cancers: Toward cancer detection and targeted therapeutics.
    Ferreira JA; Magalhães A; Gomes J; Peixoto A; Gaiteiro C; Fernandes E; Santos LL; Reis CA
    Cancer Lett; 2017 Feb; 387():32-45. PubMed ID: 26828132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced bladder tumours.
    Ferreira JA; Videira PA; Lima L; Pereira S; Silva M; Carrascal M; Severino PF; Fernandes E; Almeida A; Costa C; Vitorino R; Amaro T; Oliveira MJ; Reis CA; Dall'Olio F; Amado F; Santos LL
    Mol Oncol; 2013 Jun; 7(3):719-31. PubMed ID: 23567325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycosylation characteristics of colorectal cancer.
    Holst S; Wuhrer M; Rombouts Y
    Adv Cancer Res; 2015; 126():203-56. PubMed ID: 25727149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of glyco-mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours.
    Ricardo S; Marcos-Silva L; Pereira D; Pinto R; Almeida R; Söderberg O; Mandel U; Clausen H; Felix A; Lunet N; David L
    Mol Oncol; 2015 Feb; 9(2):503-12. PubMed ID: 25454345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycoproteomics enabled by tagging sialic acid- or galactose-terminated glycans.
    Ramya TN; Weerapana E; Cravatt BF; Paulson JC
    Glycobiology; 2013 Feb; 23(2):211-21. PubMed ID: 23070960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.